Brief: Blueprint Medicines Announces FDA Acceptance Of Supplemental New Drug Application For AYVAKIT® (Avapritinib) For The Treatment Of Indolent Systemic Mastocytosis

Blueprint Medicines

23/01/2023 13:11

Jan 23 (Reuters) - Blueprint Medicines Corp  BPMC.O :
    * BLUEPRINT MEDICINES ANNOUNCES FDA ACCEPTANCE OF
SUPPLEMENTAL NEW
DRUG APPLICATION FOR AYVAKIT® (AVAPRITINIB) FOR THE TREATMENT OF
INDOLENT SYSTEMIC MASTOCYTOSIS
    * BLUEPRINT MEDICINES CORP: FDA GRANTS PRIORITY REVIEW AND
SETS
PDUFA ACTION DATE OF MAY 22, 2023

Source text for Eikon:  ID:nPn3rWxs1a 
Further company coverage:  BPMC.O 
 ((Reuters.Briefs@thomsonreuters.com;))